Genmab Says Japan Ministry Of Health, Labour And Welfare Approved EPKINLY (epcoritamab) As The First And Only T-Cell Engaging Bispecific Antibody Treatment In Japan
Portfolio Pulse from Benzinga Newsdesk
Genmab and AbbVie have received approval from the Japan Ministry of Health, Labour and Welfare for EPKINLY (epcoritamab), the first and only T-cell engaging bispecific antibody treatment in Japan. The drug is part of the companies' oncology collaboration.
September 25, 2023 | 10:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie's partnership with Genmab on the development of EPKINLY (epcoritamab) has led to its approval in Japan. This could potentially boost AbbVie's presence in the oncology market.
The approval of EPKINLY (epcoritamab) in Japan, a drug co-developed by AbbVie and Genmab, could potentially increase AbbVie's revenues and strengthen its position in the oncology market. The news is directly relevant to AbbVie and could be important for investors tracking the company's performance in the healthcare sector.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Genmab's collaboration with AbbVie on the development of EPKINLY (epcoritamab) has resulted in its approval in Japan. This could potentially enhance Genmab's standing in the oncology market.
The approval of EPKINLY (epcoritamab) in Japan, a drug co-developed by Genmab and AbbVie, could potentially increase Genmab's revenues and strengthen its position in the oncology market. The news is directly relevant to Genmab and could be important for investors tracking the company's performance in the healthcare sector.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50